Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma by Joppi, R & Nachtnebel, A.
Horizon Scanning 
in Oncology 
Trametinib for advanced  
or metastatic BRAF V600  
mutation-positive melanoma 
 
 
DSD: Horizon Scanning in Oncology Nr. 34 
ISSN online 2076-5940 

Horizon Scanning 
in Oncology 
Trametinib for advanced  
or metastatic BRAF V600 
mutation-positive melanoma 
 
 
Vienna, December 2012 
Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft in collaboration with The Italian Horizon Scanning Project, 
Dipartimento Farmaceutico, Azienda ULSS 20, Verona/Italy 
Author(s):  Dr. Roberta Joppi, Italian Horizon Scanning by  
Dipartimento Farmaceutico, Azienda ULSS 20, Verona/Italy 
 Dr. med. Anna Nachtnebel, MSc (LBI-HTA) 
External review: Prof. Claudio Graiff 
Director of Medical Oncology Department,  
CentralHospital Bolzano – Bozen, Italy 
 
 
 
 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited 
literature search. It is not a definitive statement on safety, effectiveness or efficacy and cannot re-
place professional medical advice nor should it be used for commercial purposes. 
This product of collaboration with the Italian Horizon Scanning Project is an offspring of the Euro-
pean network for Health Technology Assessment (EUnetHTA) Project that was supported by a 
grant from the European Commission. The sole responsibility lies with the author(s), and the Com-
mission is not responsible for any use that may be made of the information contained therein. 
 
 
CONTACT INFORMATION
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nussdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for Contents: 
Ludwig Boltzmann Institute of Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize 
the research results of the Ludwig Boltzmann Institute of Health Technology Assessments. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
„http://eprints.hta.lbg.ac.at”: 
DSD: Horizon Scanning in Oncology Nr. 34 
ISSN online 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/ 
© 2012 LBI-HTA – Alle Rechte vorbehalten 
LBI-HTA | 2012 3 
1 Drug description 
Generic/Brand name/ATC code:  
Trametinib, GSK1120212/not available yet/L01X 
Developer/Company:  
GlaxoSmithKline (GSK) 
Description:  
Mutated genes are frequently present in melanomas. In particular, activat-
ing mutations in BRAF gene which resides on chromosome 7 q occur fre-
quently in human melanoma, thus constituting a possible target for molecu-
lar therapy [1]. The BRAF protein, a critical serine/threonine kinase in the 
RAS/mitogen-activated protein kinase pathway, is activated by somatic mu-
tation in about 50 % of melanoma tumours [2, 3]. The most common BRAF 
mutations involve the kinase domain, leading to constitutive activation of 
the protein, which results in an increase of its basal kinase activity. The ma-
jority of BRAF mutations (i.e. 80 %-90 %) are V600E mutations, followed by 
V600K mutations and others [2, 4]. These mutations have been found not 
only in melanoma, but also in 30-70 % of papillary thyroid tumours, in 30 % 
of serous low-grade ovarian tumours, in 15 % of cholangiocarcinomas and in 
10 % of colorectal cancers [5]. 
The first in class selective inhibitor of the BRAF serine-threonine kinase is 
vemurafenib which is approved in the USA and in Europe for melanoma 
treatment. Since mutations of BRAF result from the extracellular signal-
regulated kinase (ERK) mitogen-activated protein kinase pathway (MEK-
ERK) in unregulated cell proliferation [3, 6, 7], direct inhibition of MEK 
has also proven to be effective in reducing melanoma cell proliferation. 
Trametinib, a MEK 1/2 kinase inhibitor, reduces growth factor-mediated 
cell signalling and cellular proliferation in various cancers with mutant 
BRAF [3, 8]. Since trametinib is only indicated for malignant melanomas 
with BRAF V600 mutations, testing of presence of these mutations prior to 
treatment initiation has to be performed [7].  
Trametinib is administered orally at a recommended dose of 2 mg/day until 
disease progression or unacceptable toxicity [9]. 
2 Indication 
Trametinib is indicated for the treatment of patients with advanced (Stage 
IIIc) or metastatic (Stage IV) BRAF V600E/K mutation-positive malignant 
melanoma.  
trametinib indicated  
for metastatic 
melanoma with BRAF 
V600 mutations 
administered  
orally 2 mg/d 
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3 Current regulatory status 
Trametinib is currently neither licensed in Europe nor in the U.S., but ac-
cording to a press release GSK announced the filing of marketing applica-
tions in August 2012 [10].  
4 Burden of disease 
Melanomas are malignant tumours of melanocytes. Suspicious lesions are 
nevi (i.e. moles or birthmarks) with, for example, variable discoloration, 
growth or development of satellites [11]. Risk factors for developing mela-
nomas include prior melanomas, a positive family history and multiple clin-
ically atypical moles/dysplastic nevi. In addition, genetic factors and sun 
exposure can contribute towards the development of melanomas [12]. To 
confirm the diagnosis of melanoma a biopsy, at best by local excision, should 
be performed [11]. Median age at diagnosis is 59 years [11]. 
Staging of melanomas based on the tumour, node, metastasis (TNM) system 
includes describing the spread, aggressiveness and the size of the tumour. By 
taking into account characteristics like thickness (i.e. according to the 
Breslow criteria for microstaging), ulcerations and the mitotic rate of the 
primary tumour, by assessing the spread to regional lymph-nodes including 
satellite lesions (tumour cells separated from the primary tumour) and in-
transit metastases and by evaluating distant metastases, patients are grouped 
into four prognostic categories (stage I –IV) [13]. Other factors which influ-
ence prognosis are gender, age and localisation of the tumour where younger 
patients, women and patients with tumours on the extremities have a better 
prognosis [11]. For patients suffering from stage IV disease, sites of metasta-
ses and elevated lactate-dehydrogenase (LDH) levels are also associated with 
poor outcomes [12]. If the tumour has spread beyond near-by lymph-nodes, it 
is called advanced or metastatic melanoma which corresponds to stage IV dis-
ease. Metastases most often occur in the skin or in lymph-nodes, or in organs 
such as the lungs, the liver, the brain and in the bones. Staging is also an 
important factor for the determination of the most appropriate treatment [13].  
The majority of patients, about 85 %, present with localised disease, corre-
sponding to 5-year survival rates of up to 90 %. In about 13 % the regional 
lymph nodes are affected at diagnosis, leading to diminished survival rates 
of 20 %-70 %. About 2 %-5 % of patients present with distant metastases 
that is stage IV. Long-term survival of all patients with distant metastases is 
less than 10 % [12]. Median survival is 6 to 9 months [14]. 
In 2008, EU incidence rate (per 100,000) of skin melanoma was 14.0, being 
13.5 among males and 14.5 among females (overall cumulative risk of 0.93 %). 
Mortality rate (per 100,000) was of 2.9, being 3.2 among males and 2.5 among 
females [15]. In Austria, the incidence of melanomas is about 15 newly diag-
nosed cases/100,000 persons per year and is constantly rising [16]. In 2007, 
overall 1,100 people were newly diagnosed with malignant melanoma in 
Austria. Of those, about 5 % of the tumours were already disseminated, re-
sulting in about 60 persons with advanced melanoma per year [14]. The fre-
neither licensed in 
Europe nor in the U.S. 
risk factors for 
melanoma:  
positive family history, 
genetic factors,  
sun exposure … 
based on TNM system 
for staging, 4 prognostic 
groups are differentiated 
 
gender, age, LDH levels 
and localisation are 
important factors  
for prognosis  
 
metastatic melanoma: 
median survival of  
6-9 months 
 
 
about 30 patients/year 
with BRAF mutations  
in metastatic melanoma 
in Austria 
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quency of BRAF mutations ranges from 36 % to 45 % in primary melanomas 
and 42-55 % in metastatic melanoma. More than 75 somatic mutations in the 
BRAF gene have been identified in melanoma and all mutations at V600 (74-
90 % V600E; 16-29 % V600K) in exon 15 constitutively activate BRAF [17]. 
For Austria this means 25-33 patients present with BRAF mutations in me-
tastatic melanoma each year.  
5 Current treatment 
Treatment of un-resectable stage III melanoma and of stage IV melanomas 
focuses on symptom palliation, on preventing the tumour to spread, to re-
duce or getting rid of metastases and to maintain or achieve an acceptable 
quality-of-life [12].  
Treatment options for metastatic melanoma are: 
b Chemotherapy:  
b dacarbazine (DTIC), has been the standard comparator (as mono-
therapy) for new therapeutic regimens [12]. However, only 10 %-
20 % of patients respond to this treatment, showing mainly partial 
remissions with a median response duration of 3-4 months [12]. 
b fotemustine, also licensed for disseminated malignant melanoma, 
foremost if the tumour has spread to the brain, is an option espe-
cially for the 2nd line treatment [18]. 
b temozolomide (off-label) shows similar benefits like DTIC. Due to 
its ability to penetrate into the brain and other parts of the nervous 
system, it is often used for the treatment of patients with brain me-
tastases [13].  
b ipilimumab a monoclonal antibody targeting the CTLA-4 was approved 
only as second-line therapy of advanced melanoma in Europe in 2011 
[19].  
b vemurafenib, approved for BRAF V600 mutation-positive disease [20]. 
b high-dose interleukin-2 (licensed in the US) has shown long-lasting 
effects including complete remissions, but only in the minority of pa-
tients. Because of its serious side-effects, it remains a treatment opti-
on for patients in good condition. 
b participation in clinical trials. 
If clinical trials or approved new targeted compounds are not available, cyto-
toxic drugs such as dacarbazine (historically it had been the drug of refer-
ence), temozolomide, taxanes, fotemustine, platin derivatives or others, c-kit-
inhibitors (e.g. imatinib), cytokines (IFN, IL-2) or combinations may be ap-
plied. 
 
 
 
cure not possible 
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6 Evidence 
A literature search was conducted on the 19th of November in four databases 
(OVID, Embase, Cochrane, CRD Database) using the terms “melanoma”. 
“skin neoplasm”, “trametinib” and “GSK1120212”. After de-duplication, 113 
references were identified. Only phase III and phase II studies were eligible, 
thus one phase III trial [21] and one phase I/II trial [22] were included.  
Furthermore, Pharmastar (an Italian online newsletter website), the R&D Da-
tabase, GSK’s website, press releases – pipeline and the ASCO Congress web-
site were searched for “trametinib” in October 2012.  
The manufacturer was also contacted, but no relevant publications which 
had not yet been included were submitted.  
6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Publication title: Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [21, 23, 24] 
Official title: A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in 
Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma [25] 
Study  
identifier 
Clinical trials identifier: NCT01245062; METRIC Study  
Phase III, randomised, open-label, active-controlled trial, 2:1 randomisation, 
stratification according to baseline lactate dehydrogenase levels and status of prior 
chemotherapy 
Design 
Duration  Enrolment: November 2010 
Median follow-up: NA 
Cut-off date for primary outcome measure analysis: February 2012 
Estimated study completion date: March 2013 [25] 
Hypothesis Superiority 
The study was designed with a power of at least 99 % at a one-sided alpha level of 
0.025 to detect a relative improvement of 133 % in progression-free survival  
(hazard ratio for disease progression or death, 0.43) 
Funding GlaxoSmithKline 
Subject selection 1,022 patients were screened for V600E/K BRAF mutations from 
December 2010 – July 2011 
Overall study 
population 
(N = 322) 
322 eligible patients (281 with the V600E mutation, 40 with the 
V600K mutation, and 1 with both mutations) were randomised in 
in a 2:1 ratio to either intervention of control group 
Intervention 
(N = 214) 
2 mg/day oral trametinib  
Treatment 
groups 
Control 
(N = 108) 
dacarbazine 1000 mg/m2 of body-surface area or paclitaxel  
175 mg/m2, at the discretion of the investigator, every 3 weeks. 
 
 
 
1 phase III trial and  
1 phase I/II trial included  
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Progression-free 
survival 
(primary 
endpoint) 
PFS time from randomization until the earliest date of 
disease progression (RECIST criteria 1.1 [26]) or death 
due to any cause on the basis of the site investigator’s 
assessment  
Overall survival OS time from randomization until death due to any cause 
Best overall 
response rate 
BORR the percentage of subjects with evidence of CR or PR 
(RECIST 1.1 [26]); best overall response will be based 
on unconfirmed responses as OS/PFS are the primary 
endpoints. 
Duration of 
response 
DOR time from first documented evidence of CR or PR until 
disease progression or death due to any cause. 
Duration of response for subjects who have not 
progressed or died at the time of analysis will be 
censored at the date of their last tumour assessment. 
Endpoints 
and 
definitions 
Health related 
quality-of-life 
HRQL European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (QLQ-
C30) version 3 and the EuroQoL-5D (EQ-5D) 
Results and analysis 
Analysis  
description 
intention-to-treat (ITT) 
There were 322 patients in the ITT population, of whom 273 (85 %) were in the 
primary efficacy population. The primary efficacy population included patients with 
the V600E BRAF mutation who did not have brain metastases at baseline. 
Inclusion age: ≥18 years; 
b histologically confirmed unresectable (stage IIIc) or metastatic 
(stage IV) BRAF V600E/K mutation-positive melanoma; 
b presence of brain metastases was allowed only if they  
were stable; 
b ≤1 prior chemotherapy treatment (excluding ipilimumab, 
BRAF or MEK inhibitors); 
b ECOG PS: 0-1 
Exclusion b history of clinically significant cardiovascular or interstitial 
lung disease; 
b evidence or a risk of retinal-vein occlusion or central serous 
retinopathy 
 I C 
Analysis  
population 
Characteristics 
Median age – yr (range) 
Male sex – % 
White race – % 
ECOG – PS – 0/1 
Stage: M1a/M1b/M1c/ 
unresectable (IIIc) – % 
Previous Chemotherapy:  
No/Yes – % 
Previous immunotherapy – % 
LDH: ≤ULN/>ULN – & 
55 (23-85) 
56 
100 
64/36 
11/16/67/5 
 
67/33 
 
32 
63/36 
54 (21-77) 
49 
100 
64/36 
14/20/58/7
 
65/35 
 
28 
61/39 
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Treatment group Intervention (trametinib) Control (chemotherapy) 
Number of subjects N = 214 N = 108 
PFS, months 
Median 
95 %CI 
 
4.8 
NA 
 
1.5 
NA 
OS NR NR 
6-months OS, % 81 67 
BORR, % 
95 %CI 
22 
17-281 
8 
4-15 
Confirmed Response CR,  
n (%) 
PR, n (%) 
SD, n (%) 
PD, n (%) 
Response NR, n (%) 
 
4 (2) 
43 (20) 
119 (56) 
38 (18) 
10 (5) 
 
0 
9 (8) 
34 (31) 
50 (46) 
15 (14) 
DOR, months 
Median  
95 %CI 
 
5.5 
4.1-5.9 
 
NR 
Descriptive 
statistics and 
estimated 
variability  
HRQL NA NA 
Comparison groups  Intervention vs Control 
HR 0.45 
95 %CI 0.33-0.63 
PFS 
(by site investigator) 
P value p<0.001 
HR 0.42 
95 %CI 0.29-0.59 
PFS 
(by independent review 
blinded to treatment)  
P value ≤ 0.001 
HR 0.54 
95 %CI 0.32-0.92 
Effect 
estimate per 
comparison 
OS 
P value 0.01 
Notes According to a protocol amendment adopted on February 16, 2012, the independent 
data and safety monitoring committee and study steering committee concluded that 
both progression-free survival and overall survival were significantly longer in the 
trametinib group than in the chemotherapy group and that immediate crossover to 
trametinib should be permitted. 
NR = not reached, NA = not available, HR = Hazard ratio, ECOG PS = Eastern Coop-
erative Oncology Group Performance Status, OS = overall survival, PFS = progression free 
survival, CR = complete response, PR = partial response, SD = stable disease, PD = pro-
gressive disease, BORR = best overall response rate, CI = confidence interval, n = number, 
QoL = quality-of-life 
 
1 For I vs C: P=0.01 
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Table 2: most frequent adverse events 
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [21, 23, 24] 
Grade (according  
to CTC version 4.0) AEs, n (%) Intervention (N=211) Control (N=99) 
Rash 121 (57) 10 (10) 
Diarrhoea 91 (43) 16 (16) 
Fatigue 54 (26) 27 (27) 
Peripheral oedema 54 (26) 3 (3) 
Acneiform dermatitis 40 (19) 1 (1) 
Nausea 38 (18) 37 (37) 
Alopecia 36 (17) 19 (19) 
Hypertension 32 (15) 7 (7) 
Constipation 30 (14) 23 (23) 
All grades 
Vomiting 27 (13) 19 (19) 
Fatigue 8 (4) 3 (3) 
Peripheral oedema 2 (1) 0 
Acneiform dermatitis 2 (1) 0 
Nausea 2 (1) 1 (1) 
Alopecia 1 (<1) 0 
Hypertension 26 (12) 3 (3) 
Constipation 0 1 (1) 
Grade 3  
Vomiting 2 (1) 2 (2) 
Rash 16 (8) 0 Grade 3 or 41 
Diarrhoea 0 2 (2) 
Ocular events 9° – 
Decreased ejection fraction 14 (7)* – 
Cardiac-related events 2 (1) – 
Discontinuations due to AEs NA (35) NA (22) 
Other outcomes 
Dose-reductions NA (27) NA (10) 
1 Only one patient experienced grade 4 side-effect in each group; * = 11 decreased ejection 
fraction, and 3 left ventricular dysfunction, ° = 4 % blurred vision, <1 % reversible chorio-
retinopathy 
 
 
In this pivotal phase III, open-label trial 322 patients with histologically 
confirmed unresectable (stage IIIc) or metastatic (stage IV) melanoma har-
bouring the mutation BRAF V600E or BRAF V600K, were randomised to 
receive oral trametinib (2 mg/day) or chemotherapy (either intravenous 
dacarbazine or paclitaxel). To identify patients with these mutations, 1,022 
patients were initially screened. Of the 737 patients excluded from the study, 
the majority (458 patients) were BRAF V600 negative, 268 did not meet in-
clusion criteria and 11 patients declined [24]. Thus 281 patients were en-
rolled with BRAF V600E, 40 patients with BRAF V600K and 1 patient with 
both mutations. Choice of chemotherapy was at the investigator’s discretion. 
Of the 108 patients randomised to chemotherapy, only 99 received therapy 
of which 62 were treated with dacarbazine and 37 with paclitaxel [24].  
pivotal phase III  
with 322 patients  
with BRAF mutations  
previously treated and 
previously untreated 
 
 
comparison of 
trametinib with 
chemotherapy at the 
investigator’s discretion 
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Enrolment criteria allowed up to 1 prior therapy (excluding ipilimumab, 
BRAF or MEK inhibitors), thus about 66 % of included patients had re-
ceived chemotherapy and approximately 30 % immunotherapy. The major-
ity of patients (i.e. 78 %) were younger than 65 years, had ECOG perform-
ance status 0 (i.e. 64 %) and normal LDH levels. 
The primary efficacy analysis, conducted in the intention-to-treat popula-
tion, was based on analyses from February 2012 (the pre-specified numbers 
of PFS events had been reached in October 2011).  
According to the investigators, progression-free survival (primary endpoint) 
was 4.8 months in the trametinib group vs 1.5 months in the chemotherapy 
group (HR 0.45; 95 %CI 0.33-0.63; p<0.001). Results for subgroups accord-
ing to mutation-status and prior treatment, age, LDH levels, disease stage 
and sex mainly favoured the trametinib group. Only older patients (≥65 
years) and patients with V600K mutations did not show statistically signifi-
cant results, but both groups comprised rather few patients. 71 patients were 
≥65 years and only 40 had V600K mutations.  
Six-month overall survival rate was 81 % vs 67 % (HR for death 0.54; p=0.01); 
median OS had not been reached at time of analysis, but follow-up contin-
ues. The authors mention that these results might underestimate the differ-
ence between the two groups, because 47 % of patients in the chemotherapy 
group crossed-over to trametinib after disease progression. Overall response 
rate was 22 % vs 8 %, including complete responses of 2 % in the trametinib 
group vs 0 % in the chemotherapy groups and partial response of 20 % vs 
8 % respectively. Stable disease was observed in the trametinib group in 
56 % vs 31 % in the chemotherapy groups; the corresponding numbers for 
progressive disease were 18 % vs 46 %. Duration of response was 5.5 months 
in the trametinib group, but was not reached in the chemotherapy group.  
Most common adverse events (AE) of all grades were rash (I 57 % vs C 10 %), 
diarrhoea (I 43 % vs C 16 %), fatigue (I 26 % vs C 27 %) and nausea (I 18 % 
vs C 37 %). AEs of grade 3 were hypertension (I 12 % vs C 3 %), rash (I 8 % 
vs C 0 %), diarrhoea (I 0 % vs C 2 %), fatigue (I 4 % vs C 3 %) and nausea 
(I 1 % vs C 1 %). Of note, more dose-interruptions (I 35 % vs C 22 %) and 
dose reductions (I 27 % vs C 10 %) due to AEs were observed in the tra-
metinib group. No cutaneous squamous-cell carcinomas or hyperprolifera-
tive skin lesions were diagnosed while patients were receiving trametinib. 
Based on results for PFS and OS, the data and safety monitoring committee 
recommended allowing immediate cross-over to the trametinib group. In 
addition, a total of 8 % of patients in the trametinib group and 6 % in the 
chemotherapy group received vemurafenib, and 5 % in the trametinib group 
and no patients in the chemotherapy group received ipilimumab after the 
study therapy. Hence, even though follow-up for median OS continues, this 
result has to be interpreted with caution.  
PFS, primary outcome, 
+ 3.3 months for 
trametinib group,  
HR =0.45 
6months OS:  
I 81 % vs C 67 % 
 
but cross-over of 47 % 
in chemotherapy group 
 
ORR: I 22 % vs C 8 %, 
mainly partial responses 
 
duration of response 
was 5.5 months 
most common AEs: 
rash, diarrhoea, fatigue 
 
dose-interruptions:  
I 35 % vs C 22 % and 
dose-reductions:  
I 27 vs C 10 %  
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6.2 Efficacy and safety – further studies 
One open-label phase I/II trial comprising 247 patients with metastatic mela-
noma and BRAF V600 mutations was identified [27]. 85 patients initially re-
ceived oral dabrafenib (75 or 150 mg twice daily), an experimental BRAF 
inhibitor, and trametinib (1, 1.5, or 2 mg daily) and then 162 patients were 
randomly assigned to receive combination therapy with dabrafenib (150 mg) 
plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end 
points were the incidence of cutaneous squamous-cell carcinoma, survival 
free of melanoma progression, and response.  
19 % of patients receiving dabrafenib experienced cutaneous squamous car-
cinoma in comparison to 2 % in the dabrafenib/1mg trametinib group and 
in 7 % in the dabrafenib/2mg trametinib group. The most frequent AEs ob-
served in the combination 150/2 group were pyrexia (all grades: 71 %; grade 
3 or 4: 5 %) and chills (all grades: 58 %; grade 3 or 4: 2 %). Besides pyrexia 
and chills, other AEs more common in the dabrafenib/2mg trametinib group 
than in the mono-therapy arm were fatigue (53 %), nausea (44 %), vomiting 
(40 %), and diarrhoea (36 %). Of these, only the minority were grade 3 or 4. 
The most frequent toxic AE of grade 3 or 4 in the combination 150/2 group 
was neutropenia (11 %). Median PFS was 9.4 months in the dabrafenib/2mg 
trametinib group and 5.8 months in the dabrafenib monotherapy group (HR 
= 0.39; 95 %CI 0.25 to 0.62; p<0.001). The rate of complete or partial re-
sponse was 76 % dabrafenib/2mg trametinib group and 54 % in the mono-
therapy group (p = 0.03).  
7 Estimated costs 
No cost estimates are available for trametinib.  
8 Ongoing research 
Searching www.clinicaltrials.gov/ and www.clinicaltrialsregister.eu/  
for “trametinib”, “GSK1120212” and “melanoma” 3 phase III trials were 
identified: 
b NCT01682083: two-arm, randomized, double-blind Phase III study of 
dabrafenib in combination with trametinib versus two placebos in the 
adjuvant treatment of melanoma after surgical resection. Patients 
with completely resected, histologically confirmed, BRAF V600E/K 
mutation-positive, high-risk cutaneous melanoma will be screened for 
eligibility. Estimated study completion date: July 2015. 
b NCT01584648/EudraCT Number: 2011-006087-49: two-arm, double-
blinded, randomized, Phase III study comparing dabrafenib and trame-
tinib combination therapy to dabrafenib administered with a trame-
tinib placebo (dabrafenib monotherapy) in previously untreated pa-
tients. Subjects with histologically confirmed cutaneous melanoma 
one further phase I/II 
trial compared different 
dosages of trametinib  
+ dabrafenib and 
dabrafenib monotherapy  
best outcomes  
for dabrafenib  
+ trametinib 2 mg/d 
no cost estimates 
available 
3 on-going phase III trials 
for melanoma 
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that is either Stage IIIC or Stage IV, and BRAF V600E/K mutation 
positive will be screened f be allowed. Subjects will be followed for 
overall survival; crossover will not be permitted. Estimated study com-
pletion date: May 2015. 
b NCT01597908/EudraCT Number 2011-006088-23: two-arm, open-label, 
randomised, Phase III study comparing dabrafenib and trametinib 
combination therapy to vemurafenib in previously untreated. Subjects 
with histologically confirmed cutaneous melanoma that is either stage 
IIIc or stage IV, and BRAF V600E/K mutation positive will be 
screened for eligibility. Estimated study completion date: June 2015.  
Several phase II trials were also found for other cancer such as non-small cell 
lung cancer, thyroid cancer, mouth neoplasms, leukaemia, and metastatic 
pancreatic cancer.  
9 Commentary  
Trametinib, a MEK inhibitor, is currently neither licensed in Europe nor in 
the U.S. A phase III trial evaluated trametinib mono-therapy in comparison 
to chemotherapy in 322 patients with BRAF V600 mutation-positive mela-
noma. Included patients were either untreated (~66 %) or had received one 
prior chemotherapy (~34 %). Median PFS, the primary outcome, was pro-
longed by 3.3 months (HR 0.45; 95 %CI 0.33-0.63; p<0.001) for patients 
treated with trametinib in comparison to those treated with chemotherapy 
(68 % dacarbazine, 32 % paclitaxel). Improved results were consistent across 
subgroups with the exceptions of patients aged ≥65 years and patients with 
BRAF V600K mutations which yielded no statistically significant outcomes. 
Best overall response rates (=complete response + partial response) also fa-
voured the trametinib group (I 22 % vs C 8 %), mainly driven by partial re-
sponses (20 %). Median OS was not reached at time of this analysis, but 6 
months OS rates were 81 % in the trametinib group and 67 % in the chemo-
therapy group yielding a HR of 0.54 (95 %CI 0.32-0.92; p=0.01). Due to these 
results, crossing over from the chemotherapy group to the MEK inhibitor 
group was allowed. Further analysis of median OS will, also due to the fact 
that patients received ensuing therapies after disease progression, be com-
promised. The most frequent AEs in the trametinib group were rash, diar-
rhoea, acneiforme dermatitis and fatigue, but no case of cutaneous squamous 
cell carcinoma occurred.  
Treatment of melanoma has undergone substantial changes in the last years. 
Until recently, only few drugs with rather limited activity have been avail-
able. With the development of targeted drugs, e.g. the BRAF inhibitor ve-
murafenib or the human monoclonal antibody ipilimumab, new treatment 
options have become available. Even though no consensus on therapy exists, 
vemurafenib is often the recommended therapy for patients with BRAF V600 
mutation-positive melanoma [20]. Even though trametinib was compared at 
least in some patients with dacarbazine, which was considered reference 
standard at study initiation but has limited activity itself, direct head-to-
head comparisons of newly available agents are missing. In addition, despite 
the fact that the phase III trial had included previously untreated as well as 
previously treated patients (with chemotherapy or immunotherapy), yield-
several on-going phase II 
for other types of cancer 
trametinib not  
licensed yet 
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ing improved PFS in both subgroups, the latter group included only rela-
tively few patients (~34 %). Furthermore, if trametinib will also be active in 
patients previously treated with vemurafenib remains unknown and preclini-
cal studies indicate that acquired resistance to BRAF inhibitors (in that case 
dabrafenib) also led to a reduced sensitivity to trametinib [28]. Conversely, 
MEK mutations have also been reported to cause secondary resistance not 
only to MEK inhibitors but also cross-resistance to BRAF inhibitors [29]. 
Thus the optimal sequencing of new agents for the treatment of melanoma 
remains unknown and the population trametinib might be used for should 
be better characterised.  
Further, secondary resistance can also be held accountable for the rather 
short durations of response (between 2-18 months, median 8-9 months) to 
BRAF inhibitors [6, 28, 29]. For patients responding to trametinib (22 %), 
median duration of response was also only 5.5 months. Even though GSK ob-
viously seeks approval for single-agent trametinib as well as for dabrafenib, 
which was used in combination with trametinib in the phase I/II trial [27, 
29, 30], combining different agents is believed to delay resistance. Two on-
going phase III trials therefore investigate the combination of the BRAF in-
hibitor dabrafenib (also GSK) in combination with the MEK inhibitor trame-
tinib as first-line therapy. Results can be expected in 2013 (NCT01584648) 
and 2014 (NCT01597908). When trametinib, which costs are not yet known, 
will receive market authorization in combination with a BRAF inhibitor, 
treatment costs are likely to be substantial.  
Besides acquired resistance, primary resistance to BRAF or MEK inhibitors 
is reported to exist in less than 15 % of patients [29]. Exploring the impact 
of further mutations on clinical outcomes and choice of therapy may be use-
ful in better characterising patients for specific therapies and in determining 
optimal combination regimens [7]. Nonetheless, testing for mutations fur-
ther increases costs, foremost when not only single mutations are being 
tested [31]. Concerning selection of patients with BRAF V600 mutations the 
BRAF mutation assay used in the phase III trial, was undergoing validation 
but these results are not available yet [23], but the same test will also be used 
in the two on-going phase III studies. Besides, determination of mutation 
status, other companion diagnostics which allow prediction of duration of 
response are currently subject of research [32]. 
Besides the rather heterogeneous population (pre-treated/untreated, different 
comparators) in the phase III trial, the majority of patients were younger than 
65 years and had a performance status of grade 0, corresponding to “fully ac-
tive, able to carry on all pre-disease performance without restriction” [33]. 
More dose interruptions (I 35 % vs C 22 %) and dose-reductions (I 27 % vs 
10 %) were necessary in the trametinib group than in the chemotherapy 
group, which are likely to be even higher in older, comorbid and frail pa-
tients. Also, quality-of-life data are missing but are of utmost importance for 
patients with metastatic melanoma.  
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group rather small 
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Despite advances in the treatment of melanoma, no curative therapy exists 
and gains in either PFS or OS are incremental. Even though trametinib has 
shown activity in comparison to the former reference standard dacarbazine 
which has limited activity itself, and in previously treated as well as in pre-
viously untreated patients, the optimal sequencing of available agents as well 
as their combinations remains unknown in the absence of direct compara-
tive trials. Until then enrolment onto clinical trials might be the best strat-
egy to treat patients with advanced/metastatic malignant melanoma [34]. 
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